CA2172491A1 - Method for the treatment or prevention of eczema/dermatitis - Google Patents

Method for the treatment or prevention of eczema/dermatitis

Info

Publication number
CA2172491A1
CA2172491A1 CA002172491A CA2172491A CA2172491A1 CA 2172491 A1 CA2172491 A1 CA 2172491A1 CA 002172491 A CA002172491 A CA 002172491A CA 2172491 A CA2172491 A CA 2172491A CA 2172491 A1 CA2172491 A1 CA 2172491A1
Authority
CA
Canada
Prior art keywords
thr
ser
tyr
asn
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002172491A
Other languages
English (en)
French (fr)
Inventor
Jurgen Michaelis
Timothy Elliot Trigg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Immuni T Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2172491A1 publication Critical patent/CA2172491A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002172491A 1993-09-24 1994-09-26 Method for the treatment or prevention of eczema/dermatitis Abandoned CA2172491A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM144993 1993-09-24
AUPM1449 1993-09-24

Publications (1)

Publication Number Publication Date
CA2172491A1 true CA2172491A1 (en) 1995-03-30

Family

ID=3777229

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002172491A Abandoned CA2172491A1 (en) 1993-09-24 1994-09-26 Method for the treatment or prevention of eczema/dermatitis

Country Status (9)

Country Link
US (1) US5798335A (https=)
EP (1) EP0871466B1 (https=)
JP (1) JP3623231B2 (https=)
AU (1) AU697847B2 (https=)
CA (1) CA2172491A1 (https=)
DE (1) DE69433763T2 (https=)
DK (1) DK0871466T3 (https=)
ES (1) ES2218528T3 (https=)
WO (1) WO1995008338A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025123114A1 (pt) * 2023-12-15 2025-06-19 Chemyunion Ltda Composição cosmética, cosmecêutica e/ou farmacêutica, usos e métodos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689398A (en) * 1984-06-20 1987-08-25 Ortho Diagnostic Systems Inc. HTLV test using synthetic peptides
US6242564B1 (en) * 1986-06-03 2001-06-05 Candace B. Pert Treatment of tropical spastic paresis with peptide T
US5189022A (en) * 1988-05-27 1993-02-23 The United States Of America As Represented By The Secretary Of Health And Human Services Composition for the treatment of chronic fatigue syndrome
US5063206A (en) * 1988-12-16 1991-11-05 The United States Of Americas As Represented By The Department Of Health And Human Services Compositions having use as treatment of neuropsychiatric deficits
WO1989012067A1 (en) * 1988-05-27 1989-12-14 The United States Of America, As Represented By Th Compositions having use as treatment of psoriasis and neuropsychiatric deficits
DK31991D0 (da) * 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
ATE194495T1 (de) * 1992-03-27 2000-07-15 Advanced Immunit T Inc T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose
US5651993A (en) * 1992-11-18 1997-07-29 Yale University Specific immune system modulation

Also Published As

Publication number Publication date
EP0871466A1 (en) 1998-10-21
EP0871466B1 (en) 2004-05-06
DE69433763T2 (de) 2005-04-14
JP3623231B2 (ja) 2005-02-23
EP0871466A4 (https=) 1998-11-11
AU7735094A (en) 1995-04-10
WO1995008338A1 (en) 1995-03-30
ES2218528T3 (es) 2004-11-16
AU697847B2 (en) 1998-10-15
US5798335A (en) 1998-08-25
JPH09506860A (ja) 1997-07-08
DE69433763D1 (de) 2004-06-09
DK0871466T3 (da) 2004-08-16

Similar Documents

Publication Publication Date Title
US4617149A (en) Growth hormone release factor analogs
FI126143B (en) Polymyxine derivative and its uses
IL94939A (en) Transformed Analogs of Maginin Peptide and Their Use
CA2533421A1 (en) Use of xmp-629 for the treatment of acne
ATE392428T1 (de) Arzneimittel enthaltend analgetische peptide
EP0871466B1 (en) Linear and cyclic peptides for the treatment or prevention of eczema/dermatitis
US4481194A (en) Des-proline-des-glycine vasopressin antagonists
US4481193A (en) Des-proline vasopressin antagonists
EP0269299A2 (en) Atrial peptides
US4597901A (en) β-indolylalanyl or β-indolylglycinyl vasopressin antagonists
AU2004216443B2 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
WO2004028457A3 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY
US5795858A (en) Treatment or prevention of Crohn's disease and/or ulcerative colitis
JP2877908B2 (ja) 抗ヘルペスペンタペプチド類
RU95120588A (ru) Циклогексапептиды, их смеси, способ их получения и применения
US4719199A (en) Diuretic compositions and methods of producing diuresis
US4684716A (en) Polypeptide intermediates
RU98100066A (ru) Производные имидазо [1,5a] пиридина как ингибиторы серинпротеаз
JPS6267100A (ja) バソプレシン化合物
WO1998013032A1 (en) Compositions of therapeutic agents suitable for oral administration
RU2002124494A (ru) Ингибиторы интегрина αvβ6
JPH05339288A (ja) Ｈｉｖ感染阻止活性を有するペプチド
RU98104123A (ru) Химические соединения

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued